Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Astellas

Status: Completed

Conditions: Cardiovascular Disease; Overactive Bladder

Treatments: Drug: Mirabegron

Study type: Observational

Funder types: Industry

Identifiers

NCT02570035

BE0003

Details and patient eligibility

About

This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.

Enrollment: 316 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• having coexisting cardiovascular disease or a history of cardiovascular diseases
• having electrocardiogram record conducted within seven days before the start of the mirabegron treatment (including the first day of administration)

Exclusion criteria

• having serious cardiovascular disease
• having significant long QT (QTc > 500 msec)

Trial design

316 participants in 1 patient group

Mirabegron group

Description:

Subjects with overactive bladder and cardiovascular disease prescribed mirabegron

Treatment:

Drug: Mirabegron